Table 1.

Summary of Cases Examined

ID	Age (years)	Gender	Apo E	Senile plaques	CAA	NFT	TS-insoluble Aβ40/Aβ42 (pmol/g)	LDM-Aβ40/Aβ42 (pmol/g)
95848*	48	M	3 /3	−	−	−	1.74 /0.28	0.80 /0.32
23*	53	M	3 /4	−	−	−	1.44 /0.38	0.41 /0.23
97971*	44	M	3 /3	n.d.	n.d.	n.d.	2.25 /0.54	0.67 /0.12
95348*	40	M	3 /3	n.d.	n.d.	n.d.	1.30 /0.56	0.62 /0.19
90235*	22	M	3 /4	−	−	−	2.90 /0.60	0.91 /0.24
99579*	37	M	3 /3	n.d.	n.d.	n.d.	3.00 /1.14	0.33 /0.17
96393*	28	F	3 /3	−	−	−	3.34 /1.14	0.44 /0.06
96078*	33	F	3 /3	−	−	+/−	3.60 /1.14	0.56 /0.19
51*	63	F	3 /3	−	−	−	4.18 /1.40	0.94 /0.43
28*	68	M	3 /3	−	−	−	2.88 /2.40	0.48 /0.29
41*	57	M	3 /3	+/−	−	−	2.40 /3.24	1.19 /0.11
9*	59	M	3 /3	+/−	−	−	1.92 /4.20	0.54 /0.64
27	65	M	3 /4	−	−	−	3.03 /10.7	0.53 /0.53
45	69	M	3 /4	−	+	−	5.25 /20.0	0.98 /1.31
16	57	F	3 /3	−	+	−	5.30 /47.2	0.62 /0.57
33	59	M	3 /4	−	−	−	4.18 /53.6	1.23 /7.33
47	64	M	3 /4	−	−	−	8.26 /67.5	0.99 /0.45
4	79	F	3 /4	+	−	−	14.9 /95.3	2.94 /6.86
96249	46	M	3 /4	n.d.	n.d.	n.d.	6.20 /113.1	1.73 /8.92
8	60	M	3 /3	+	−	−	12.7 /211.1	2.39 /80.8
7	68	M	3 /4	++	−	−	19.5 /211.4	1.02 /4.36
30	50	M	4 /4	−	+	−	17.7 /376.5	1.27 /5.63
43	79	M	3 /4	++	−	−	19.1 /658.0	1.30 /196.5
11	58	M	3 /3	++	−	−	11.7 /1300.6	1.26 /232.3
15	71	M	3 /4	+++	−	+	682.7 /4862.2	8.46 /1197.7
55	74	M	3 /4	+++	+	+	26.1 /5152.0	3.60 /849.7
34	79	M	3 /3	++	−	−	19.7 /6379.6	1.81 /1333.1
19	75	F	3 /3	+++	−	++	25.3 /8903.5	5.27 /462.0

CAA, cerebral amyloid angiopathy; NFT, neurofibrillary tangle; n.d., not determined.

Cases 15, 55, and 19, in which NFTs are observed, may fall into Braak stages III, III, and IV by AT8 immunostaining, respectively.

*Normal cases, defined as having TS-insoluble Aβ42 levels below 5 pmol/g.